On Tuesday, Viking Therapeutics, Inc. (NASDAQ:VKTX) highlighted the final results from its VOYAGE Phase 2b trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH, also ...

The Fatty Liver Alliance raises awareness about the risks, causes and complications of fatty liver disease and helps those already diagnosed with NAFLD and NASH by advocating for access to approved ...

Paris (Reuters) - French biopharmaceutical company Genfit said on Monday it is to launch a phase 3 study of its treatment for liver disease NASH by year-end as part of an accelerated approval ...

--Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis, today announced results from new analyses of the Phase 3 ...

CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH) ...

Background: The changes in the liver in nonalcoholic fatty liver disease (NAFLD) range over a wide spectrum, extending from steatosis to steatohepatitis (NASH). However it has remained difficult to ...

Bill Sibold, Chief Executive Officer of Madrigal, stated, “NASH with moderate to advanced liver fibrosis is a serious and progressive liver disease that, until now, has not had an FDA-approved therapy ...

Enhanced Liver Fibrosis (ELF™) Test Gauges Likelihood of Disease Progression; Expands Labcorp’s Testing Options for Nonalcoholic Fatty Liver Disease The ELF test provides a numeric score to people ...

SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--Phase 2 clinical results with HTD1801, a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while ...

Imagine sitting in a doctor’s office and being told you have “non-alcoholic” liver disease. Before the doctor even finishes explaining what that means, your brain is already doing gymnastics trying to ...